Ernexa Therapeutics Inc. SEC filings ERNA
Ernexa Therapeutics Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jun 3, 2010. Its latest annual report, Form ARS, was filed on May 11, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 11, 2026 | — |
| DEF 14A | Proxy statement | May 11, 2026 | May 11, 2026 |
| DEF 14C | Information statement | Apr 13, 2026 | Apr 13, 2026 |
| PRE 14C | Filing | Apr 1, 2026 | Apr 1, 2026 |
| DEF 14A | Proxy statement | Apr 14, 2025 | Dec 31, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 3, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Oct 7, 2024 | Oct 7, 2024 |
| PRE 14A | Preliminary proxy statement | Sep 27, 2024 | Sep 27, 2024 |
| DEFA14A | Additional proxy material | May 10, 2023 | — |
| DEFA14A | Additional proxy material | May 5, 2023 | — |
| DEF 14A | Proxy statement | May 5, 2023 | Jun 16, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2023 | Jun 16, 2023 |
| DEFA14A | Additional proxy material | Aug 12, 2022 | — |
| DEF 14A | Proxy statement | Aug 12, 2022 | Sep 21, 2022 |
| PRE 14A | Preliminary proxy statement | Aug 2, 2022 | Sep 21, 2022 |
| DEFA14A | Additional proxy material | May 31, 2022 | — |
| DEFA14A | Additional proxy material | Apr 26, 2022 | — |
| DEF 14A | Proxy statement | Apr 26, 2022 | Jun 7, 2022 |
| DEFA14A | Additional proxy material | Aug 20, 2021 | — |
| DEFA14A | Additional proxy material | Jul 26, 2021 | — |
| DEFA14A | Additional proxy material | Jul 1, 2021 | — |
| DEF 14A | Proxy statement | Jul 1, 2021 | Aug 20, 2021 |
| PRE 14A | Preliminary proxy statement | Jun 21, 2021 | Aug 20, 2021 |
| DEF 14A | Proxy statement | Apr 26, 2019 | Apr 26, 2019 |
| DEFA14A | Additional proxy material | Apr 26, 2019 | — |
| DEF 14A | Proxy statement | Apr 27, 2018 | Apr 27, 2018 |
| DEFA14A | Additional proxy material | Apr 27, 2018 | — |
| DEFA14A | Additional proxy material | Apr 28, 2017 | — |
| DEF 14A | Proxy statement | Apr 28, 2017 | Apr 28, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2017 | Apr 10, 2017 |
| DEFA14A | Additional proxy material | Apr 22, 2016 | — |
| DEF 14A | Proxy statement | Apr 22, 2016 | Apr 22, 2016 |
| PRE 14A | Preliminary proxy statement | Apr 7, 2016 | Apr 7, 2016 |
| DEFA14A | Additional proxy material | Apr 24, 2015 | — |
| DEF 14A | Proxy statement | Apr 24, 2015 | Jun 5, 2015 |
| DEFA14A | Additional proxy material | Apr 25, 2014 | — |
| DEF 14A | Proxy statement | Apr 25, 2014 | Jun 6, 2014 |
| DEFA14A | Additional proxy material | May 10, 2013 | — |
| DEF 14A | Proxy statement | Apr 26, 2013 | Jun 7, 2013 |
| DEFA14A | Additional proxy material | Apr 12, 2013 | — |
| PRE 14A | Preliminary proxy statement | Apr 12, 2013 | Jun 7, 2013 |
| DEF 14A | Proxy statement | Apr 27, 2012 | Jun 8, 2012 |
| DEF 14A | Proxy statement | Apr 29, 2011 | Jun 17, 2011 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2011 | Jun 17, 2011 |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ERNA (Nasdaq), ERNAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 748592
- Former names
- Eterna Therapeutics Inc. (until Apr 4, 2025); Brooklyn ImmunoTherapeutics, Inc. (until Oct 14, 2022); NTN BUZZTIME INC (until Mar 23, 2021); NTN COMMUNICATIONS INC (until Dec 20, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.